AU3445100A - Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists - Google Patents

Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Info

Publication number
AU3445100A
AU3445100A AU3445100A AU3445100A AU3445100A AU 3445100 A AU3445100 A AU 3445100A AU 3445100 A AU3445100 A AU 3445100A AU 3445100 A AU3445100 A AU 3445100A AU 3445100 A AU3445100 A AU 3445100A
Authority
AU
Australia
Prior art keywords
antagonists
treatment
formula
prostanoid
headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU3445100A
Other languages
English (en)
Inventor
Gordon Smith Baxter
Robert Alexander Coleman
Nicholas Tilford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagene Laboratories Ltd
Original Assignee
Pharmagene Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Laboratories Ltd filed Critical Pharmagene Laboratories Ltd
Publication of AU3445100A publication Critical patent/AU3445100A/xx
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU3445100A 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists Pending AU3445100A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/001138 WO2001072302A1 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Publications (1)

Publication Number Publication Date
AU3445100A true AU3445100A (en) 2001-10-08

Family

ID=9883925

Family Applications (2)

Application Number Title Priority Date Filing Date
AU3445100A Pending AU3445100A (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
AU2000234451A Ceased AU2000234451B2 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2000234451A Ceased AU2000234451B2 (en) 2000-03-24 2000-03-24 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists

Country Status (8)

Country Link
EP (1) EP1267867B1 (https=)
JP (1) JP2003528144A (https=)
AT (1) ATE395058T1 (https=)
AU (2) AU3445100A (https=)
CA (1) CA2402099C (https=)
DE (1) DE60038902D1 (https=)
DK (1) DK1267867T3 (https=)
WO (1) WO2001072302A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2679175C (en) * 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046714C (zh) * 1993-12-20 1999-11-24 藤泽药品工业株式会社 二芳基噁唑衍生物及其制法、应用和药物组合物
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AU6836200A (en) * 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer

Also Published As

Publication number Publication date
CA2402099A1 (en) 2001-10-04
JP2003528144A (ja) 2003-09-24
ATE395058T1 (de) 2008-05-15
WO2001072302A1 (en) 2001-10-04
EP1267867B1 (en) 2008-05-14
EP1267867A1 (en) 2003-01-02
AU2000234451B2 (en) 2005-09-29
DE60038902D1 (de) 2008-06-26
CA2402099C (en) 2011-04-26
DK1267867T3 (da) 2008-08-25

Similar Documents

Publication Publication Date Title
CZ305838B6 (cs) N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
NO20015226D0 (no) Tri-aryl syrederivater som PPAR reseptor ligander
MXPA05010652A (es) Pirazoles sustituidos.
MXPA04004457A (es) Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina.
BRPI0413233A (pt) novos compostos
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
AU3445100A (en) Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
ATE438398T1 (de) Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
GB0324269D0 (en) EP4 receptor antagonists
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
ATE411287T1 (de) Neue metallproteinaseinhibitoren
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
MXPA05010651A (es) Compuestos de pirazol.
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
PE14896A1 (es) Aminoalcanimidazoles y triazoles acilados
MX2007007725A (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina (amida, sulfonamida, carbamato y urea), como antagonistas de los receptores cb1 de los cannabinoides.
PT1115404E (pt) Utilizacao de antagonistas prostanoides para o tratamento de cefaleias primarias
MXPA04004802A (es) Derivados del 1,2,4-triazol que contienen un grupo sulfamato como inhibidores de aromatasa.
NO20021879L (no) Bisykliske vasopressinagonister
MXPA05010650A (es) Pirazoles sustituidos.
EP1786815A4 (en) SPIRO COMPOUNDS AND METHOD FOR MODULATING CHEMOKIN RECEPTOR ACTIVITY